Tiago Marques

CIK: 0001875240

Transaction Breakdown

Open Market Buys (P)1 (25.0%)

High conviction signal

Open Market Sales (S)1 (25.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KTTA

Pasithea Therapeutics Corp.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

KTTA
Pasithea Therapeutics Corp.
May 1, 2026
Award(A)
Stock Option (right to buy)
Direct
1.8M shares-
KTTA
Pasithea Therapeutics Corp.
Nov 28, 2025
Purchase(P)
Direct
33.3K shares at avg. $0.75$25K
KTTA
Pasithea Therapeutics Corp.
Oct 24, 2025
Award(A)
Stock Option (right to buy)
Direct
493.3K shares-
KTTA
Pasithea Therapeutics Corp.
May 12, 2025
Sale(S)
Direct
960 shares at avg. $0.82$792

		Type	Shares	Price		Ownership
May 1, 2026	KTTA Pasithea Therapeutics Corp.	Award(A) Stock Option (right to buy)	1,756,069	-	-	Direct
Nov 28, 2025	KTTA Pasithea Therapeutics Corp.	Purchase(P)	33,333	$0.75	$25,000	Direct
Oct 24, 2025	KTTA Pasithea Therapeutics Corp.	Award(A) Stock Option (right to buy)	493,341	-	-	Direct
May 12, 2025	KTTA Pasithea Therapeutics Corp.	Sale(S)	960	$0.82	$792	Direct

1-4 of 4 transactions

About Marques Tiago

Marques Tiago (SEC CIK 0001875240) files insider reports with the SEC as Chief Executive Officer of Pasithea Therapeutics Corp. (KTTA).

Signal8 holds 4 ownership filings by Marques Tiago, all Form 4s, filed between May 14, 2025 and May 5, 2026. Those filings report 4 transactions, from May 12, 2025 to May 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Marques Tiago's filings is in MIAMI BEACH, FL.

Recent filings by Marques Tiago

May 1, 2026: Grant or award of KTTA derivative securities (Form 4, code A).
Nov 28, 2025: Open-market purchase of KTTA shares (Form 4, code P).
Oct 24, 2025: Grant or award of KTTA derivative securities (Form 4, code A).
May 12, 2025: Open-market sale of KTTA shares (Form 4, code S).

Other insiders filing for Pasithea Therapeutics Corp. (KTTA)

Coastlands Capital LP, 10% Owner
STEINMAN LAWRENCE, Director
Dumesnil Simon, Director
Schneiderman Daniel H, Chief Financial Officer
Krishnan Kartik, Chief Medical Officer
Leahy Emer, Director

How to read Form 4 transaction codes